Past, Present, and Future Roles of Therapeutic Drug Monitoring in Optimizing Biologic Therapy
Video recorded on April 24, 2025
Note: No credit is offered for this presentation.
Overview
Inflammatory bowel disease (IBD) is classified as either Crohn’s disease or ulcerative colitis, based on clinical presentation, endoscopic findings, histopathology, and disease distribution. In some cases, overlapping features may be observed. Laboratory testing plays an important role in refining diagnosis and guiding targeted therapy. Effective IBD management centers on controlling inflammation to relieve symptoms and prevent disease progression. The advent of biologic therapies, particularly anti–tumor necrosis factor (anti-TNF) agents, has transformed treatment approaches. Current therapeutic goals emphasize not only symptom relief but also sustained suppression of intestinal inflammation.
Presenter
Jami Kinnucan, M.D.
Consultant
Department of Gastroenterology and Hepatology
Mayo Clinic, Jacksonville, Florida
Intended audience
This webinar is appropriate for laboratory administrators and managers, quality assurance and control staff, supervisors, and other laboratory personnel who are dedicated to continuous quality and process improvement.
Faculty disclosure
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Questions
Contact us: mcleducation@mayo.edu
